The human dopamine transporter (DAT, SLC6A3) is an important 15 exon gene for dopamine neurotransmission and dopamine recycling. Common exon 15 variable number tandem repeat variants can be associated with attention deficit/hyperactivity disorder. Rarer single nucleotide polymorphisms produce missense variants including V55A and V382A. We now report studies of the functional influences of these DAT protein-coding variants. In COS cell transient-expression assays, V382A displays about half of the dopamine uptake velocity V max and cocaine analog binding B max values of wildtype DAT. V382A lowers dopamine's potency in inhibiting cocaine analog binding by six-fold. Cells expressing V382A or mixtures of V382A and wildtype DAT both display reduced plasma membrane and increased perinuclear expression, consistent with dominant effects of V328A on expression. V55A expresses normally but reveals a 1.7-fold-lower K m for dopamine uptake. Individuals with these human DAT protein variants could display altered dopamine systems.
INTRODUCTION
The dopamine transporter (DAT) is a putative 12 transmembrane domain protein that takes up dopamine into neurons of brain pathways including those that modulate mood and movement. DAT uptake of dopamine is blocked by cocaine, amphetamine, and other psychostimulants. This blockade is thought to play important roles in psychostimulant reward. Altered DAT expression in knockout mice alters locomotion, learning, and circadian/sleep processes. [1] [2] [3] In studies elucidating the 15 exons of the human DAT gene and its allelic variants, we have previously described common allelic variants in DAT 3 0 genomic regions including a variable number tandem repeat (VNTR) in DAT exon 15, which encodes the 3 0 untranslated region of DAT mRNA. 4 This DAT polymorphic marker has been reproducibly associated with vulnerability to attention deficit/hyperactivity disorder (ADHD) and variably linked with several other psychotic or movement disorders. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Psychostimulant DAT blockers such as methylphenidate are used to treat symptoms of ADHD and narcoleptic sleep disorders. 18, 19 Understanding the nature of human variation at this DAT locus could thus be important for understanding mechanisms of individual difference in movement, disease vulnerability and individual differences in response to psychostimulants.
Alterations in DAT's amino-acid sequence can influence DAT activities. Mutagenesis studies show that many single amino-acid mutations can alter DAT's abilities to transport dopamine, bind cocaine analogs, and/or appropriately target to the plasma membrane. [20] [21] [22] [23] [24] [25] We have sought human DAT protein coding variants using exon sequencing and single-stranded conformational polymorphism (SSCP) studies of large numbers of individuals from populations enriched in ADHD and other disorders with which DAT associations have been reported. 26 These studies have provided evidence for alanine/valine substitution variants V55A, located in DAT's intracellular N-terminus in current models of this protein, and V382A, located in DAT's fourth extracellular loop. 26 We now report studies of the effects of these allelic variations on DAT expression and function. These studies provide some of the first evidence that human DAT sequence variations can display altered activity and remarkably disrupted patterns of cellular expression. Figure 2c ). This difference paralleled the decreased uptake V max noted for the same mutant ( Figure 1 ).
RESULTS

Dopamine is Less Potent in Competing for [
3 H]CFT Binding in Cells Expressing V382A than in Cells Expressing Wildtype DAT Dopamine inhibited CFT binding to wildtype and both hDAT variants (Figure 3) , with K i values 1.1 mM for the wildtype, 0.98 mM for V55A and 7.0 mM for V382A. Values for V382A differed significantly from those of wildtype DAT. Further competition experiments examined the potencies of eight small molecules in inhibiting dopamine uptake into cells expressing each of the three DATs (Table 1) . Cocaine, benztropine and GBR12909 were significantly more potent in inhibiting dopamine uptake into cells expressing V382A by 1.3-, 1.3-and 1.6-fold, respectively, than into cells expressing wildtype DAT. Neither dopamine, methylphenidate, mazindol, nomifensine nor d-amphetamine displayed such differences at V382A and none of the eight molecules displayed significantly changed potency in cells expressing V55A. 
V382A Displayed Intracellular Expression Dominant to the Wildtype hDAT
Possible dominant effects of V382A on the expression of coexpressed wildtype DAT were also explored using differential immunofluorescent labeling and differentially tagged DAT fusion proteins. N-termini of wildtype and V382A DATs were each tagged with both FLAG and c-myc epitopes to create FLAG-WT, c-myc-WT, FLAG-V382A and c-myc-V382A (see Materials and Methods c-myc-wildtype and FLAG-wildtype DAT fusion proteins were expressed in COS cell plasma membranes in patterns 
FLAG-V382A/c-myc-V382A. When doubly-labeled cells were examined by an observer blinded to genotype to quantitate the fraction which expressed WT patterns of immunoreactivity, we observed that cells that coexpressed c-myc-WT and FLAG-WT proteins displayed near-wildtype patterns of immunoreactivity most concentrated in their plasma membrane regions (Figure 5c ). Cells that coexpressed (Figure 5d and f) c-myc-wildtype and FLAG-V382A frequently displayed immunoreactivity in perinuclear zones that was labeled with antibodies to both epitopes (Figure 5e and f) . When an observer blind to genotype quantitated these results, 66% of the doubly stained cells displayed wildtype patterns for FLAG-WT /c-myc-WT, 33% for FLAG-WT/c-myc-V382A, 36% for c-myc-WT/FLAG-V382A and 44% for FLAG-V382A/c-myc-V382A. An average of 35% of doubly-labeled cells thus displayed wildtype patterns for wildtype/V382A: FLAG-WT/c-myc-V382A and c-myc-WT/FLAG-V382A (Figure 5g ).
DISCUSSION
Our current data indicate that two naturally occurring human DAT variants display different effects on DAT expression patterns, pharmacology and physiology. These results can be discussed in light of the differential influences of these variants in COS cell expression systems, the possible relationship of these effects to the phenotypes of DAT overor underexpressing mice and the limitations of the methods employed for accurately predicting the in vivo effects of these variants. The low frequency of these protein variants within the population and the contrastingly higher frequencies of DAT promoter region haplotypes that appear to influence DAT expression are also considered. Together with data from the other rare DAT protein coding variants, 27 we now appear to have the opportunity to place most of the allelic variation at the DAT locus in Caucasian populations into tentative functional contexts.
V55A and V382A exert different magnitudes of effects on DAT expression in COS cells. The sizes of these effects are roughly inversely related to their population frequencies and the degree to which the wildtype amino acid is conserved in DAT-family transporters from various species. Large, even dominant, effects of V382A on DAT plasma membrane targeting and V max for dopamine are consistent with the low frequency of this variant in human populations studied, assuming that deviations from the predominant wildtype DAT sequence could have adverse consequences on survival. The high conservation of the wildtype valine 382 in DAT, SERT, and NET transporters from several species as well as human GABA and glycine transporters is consistent with important roles for the wildtype V382 at this position. The more modest effects of the V55A on uptake and lack of clear effect on cellular expression patterns fit with the more modest conservation of amino acids at this position in other transporters. The valine found at this position in human, mouse and rat DATs is substituted by threonine in bovine DAT and in serotonin transporters (SERTs) from several species.
The degree to which each of these mutants alters DAT functions can also fit with the positions of these amino acids in DAT's structure. V55A is placed in the cytoplasmic, N-terminal region of current DAT models. This is a domain in which each of the monoamine transporters differ from each other dramatically, and a region where substitutions for amino acids including eight possible phosphoacceptor sites fails to dramatically alter DAT expression or function (ZL and GRU, in preparation). The location of V382A, in the fourth extracellular loop, is within 10 amino acids of the location of an experimental rat DAT F391A mutation that also substantially reduces expression. 21 Substitutions for several important residues in other extracellular loops, including cysteines and asparagines in DAT's large second extracellular loop can also dramatically reduce expression levels. 28 Such combined data are consistent with the idea that this fourth loop is important for DAT expression. The dominant effects on expression conferred by V382A on coexpressed wildtype DAT is consistent with ideas that DAT may oligomerize 29 prior to its targeting the plasma membrane, that oligomers comprising V382A DAT and wildtype DAT are rapidly removed from the plasma membrane, or that the dysfunctional V382A DAT could 'clog' Golgi apparatus and other mechanisms required for normal trafficking of both wildtype and mutant DATs.
The results of the current studies have limitations which should be kept in mind when using in vitro results to predict possible in vivo effects of these variants. Although we have utilized standard expression systems, the current results were not obtained in dopaminergic neurons. Dopamine cells obtained from fetal midbrains can be grown in culture with substantial difficulty, but are difficult to transfect and express only low levels of their endogenous DAT. 30 While we believe that the current results should be applicable to in vivo expression, such extension of the current data awaits further studies. The current immunostaining approaches have been validated using studies of cells transfected with different plasmids, antisera blocked with the immunizing peptides, selective recognition of immunoreactivity in dopamine-containing and nondopaminergic tissue sections, immunoprecipitation studies, comparisons with results from protein crosslinking using cocaine analogs, and comparisons of immunostaining with biochemical biotinylation experiments on stably expressing rat DAT variants that also alter plasma membrane expression patterns (ZL and GRU, in preparation). 21, [31] [32] [33] [34] [35] We have previously assessed a number of ways to adequately describe the patterns of DAT immunoreactivity in expressing COS cells. The current method of describing the fraction of cells that appear to express in wildtype patterns has been reasonably robust and validated through hDAT variants, activity and expression
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blinded-observer examinations for a number of mutants. 21 Nevertheless, it is likely to represent only a portion of the complexity of the trafficking alterations that DAT mutants can produce, and the changes in cellular function that miscompartmentalized transporter proteins could cause. Experiments using fused myc and FLAG epitopes need to be interpreted in light of the substantial additions to the size of DATs that these fusion constructions produce in order to allow differential detection of differently tagged DATs. We do find that wildtype DAT DAB immmunostaining with good anti-DAT sera reveals wildtype expression patterns in 12% more cells than those that express epitopetagged DAT fusion proteins (Figures 4d vs 5g) . Cells expressing DAT fusion constructs also revealed more perinuclear staining (insert, Figure 5e ). The effects of epitope tagging on DAT function are also worth noting (Figure 5a and Results). Each of these patterns lends a modest but real caution to interpretation of studies using these fusion proteins.
In extensive mutagenesis studies that have characterized DAT variants that are not found naturally, we have discovered a number of amino-acid substitutions that differentially alter DAT's ability to take up dopamine vs its ability to recognize cocaine analogs. V382A displays some of these differential effects. This mutant alters dopamine's potency in competing for CFT binding in accord with the way in which it alters cocaine's potency in blocking dopamine uptake. V382A thus favors cocaine's ability to inhibit dopamine uptake. Conceivably, a V382A human homozygote might be likely to display a phenotype that included altered sensitivities to the locomotor and other consequences of cocaine's blockade of DAT; heterozygotes could even have evidence for such phenotypes as well. Such findings are not observed for V55A.
One way to think about human phenotypes that might relate to V382A is to examine effects of DAT variation in transgenic and knockout mice. Mice with one-third greater expression than wildtype or one-half less expression than wildtype mice have distinctive phenotypes, or trends toward the distinctive phenotypes found in homozygote knockouts. These include different responses to dopaminergic toxins, locomotor effects including psychostimulant effects on locomotion, changes in sleep, and (when combined with variation at other transporters) alterations in psychostimulant reward. 3, 36, 37 These observations, and preceding findings that link DAT variants to ADHD, each suggest that the variants that we have studied here could contribute selectively to individual differences in some of these phenotypes in humans. Further studies of these protein coding variants, the A559V in TM12 and E602G in C-terminal human variants recently reported by others, 27 and the much more common allelic variation in the 5 0 DAT flanking region (ZL and GRU, in preparation) could each help to elucidate the range of human variation at this important locus for locomotion, reward, psychostimulant actions and, possibly, dopaminergic degenerations.
MATERIALS AND METHODS
Mutagenesis
The 3.9 kb hDAT cDNA fragment was liberated from a preexisting plasmid pcDNA/Neo-hDAT 4 by HindIII restriction digestion and ligated into pcDNA3.1 + in the same restriction site and the resulting new plasmid designated pcDNA3.1-hDAT (wildtype hDAT or WT). Mutagenesis was carried out based on a two-step PCR protocol. 38 Mutagenic oligo is 5 0 -CAGAGCCCCGCGGAGGCCCA-3 0 for V55A and 5 0 -CCATCGGGGACGCGGCCAAGGAC-3 0 for V382A (alanine codon in bold). After PCR reactions using appropriate primers, a 0.8 kb NheI (located in the vector pcDNA3.1 + )-BamHI fragment (V55A) or 0.77 kb ScaI-ClaI (V382A) PCR product was digested with the indicated enzymes and shuttled into pcDNA3.1-hDAT, resulting pcDNA3.1-hDAT/ V55A and pcDNA3.1-hDAT/V382A, respectively. Both PCR products were confirmed by DNA sequencing.
N-terminal Tagging of Wildtype hDAT and V382A with FLAG and c-myc N-terminal tagging was carried out by PCR. The tagging oligo (or 5 0 primer) was 5
0 for c-myc (in bold). A common 3 0 primer was 5 0 -AGGCCCGAGCTGTCTCCAC-3 0 and pcDNA3.1-hDAT plasmid DNA used as the template. A 0.7 kb KpnI (located in the vector pcDNA3.1 + )-BamHI PCR product was shuttled into pcDNA3.1-hDAT and pcDNA3.1-hDAT/V382A in each case, resulting in four constructs: pcDNA3.1-FLAGhDAT (FLAG-WT), pcDNA3.1-FLAG-hDAT/V382A (FLAG-V382A), pcDNA3.1-myc-hDAT (c-myc-WT), and pcDNA3.1-myc-hDAT/V382A (c-myc-V328A). Both PCR products were confirmed by DNA sequencing.
Transient Expression in COS Cells
The methods for examining cells expressing single DNAs have been described before. 21 Average transfection efficiency was 17.4%, based on immunohistochemical staining data. To study possible interactive effects, some COS cells were transfected by 20 mg of wildtype hDAT plasmid DNA (WT/WT), 10 mg of wildtype hDAT mixed with 10 mg of V382A plasmid DNAs (WT/V382A), or 20 mg of V382A plasmid DNA (V382A/V382A) and grown on coverslips for 2 days. Cells were fixed, DAT immunostained, and stained coverslips were examined for the patterns of DAT immunoreactivity by an observer unaware of the plasmids expressed in each cell as described below. ) grown to confluence in flasks in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) containing 10% FCS (Invitrogen) were split 1 : 2, harvested hDAT variants, activity and expression Z Lin and GR Uhl the next day using trypsin/EDTA, centrifuged (200 Â g) for 10 min at 41C, washed with sterile HEBS (20 mM HEPES, 137 mM NaCl, 5 mM KCl, 0.7 mM Na 2 HPO 4 , and 6 mM dextrose), recentrifuged, and resuspended at 10 7 cells/ml in 41C HEBS. Then, 0.9 ml of suspended cells was transfected by electroporation at 300 V and 1100 mF in 400-mm Gene Pulser cuvettes (Bio-Rad) containing 20 mg of plasmid DNA and 500 mg of fish sperm DNA (Boehringer-Mannheim, Mannheim, Germany) using a geneZAPPER 450/2500 (IBI, New Haven, CT, USA). The transfected cells were suspended in complete DMEM, followed by distribution into six-well plates. Cells were grown for 2.5 days and then assayed for their abilities to accumulate [ Kinetic and saturation analyses were used to determine K M , V max , K D , and B max values as described. 39 For uptake assays, 10 nM [
3 H]dopamine and 0.1, 1, 5, 10, 20, 30, and 50 mM unlabeled dopamine concentrations were used. Pargyline (50 mM), 1 mM RO 41-0960 (catechol-O-methyl transferase inhibitor; RBI, Natick, MA, USA), and 50 mM ascorbic acid were included in assay buffers.
For initial binding assays, 2 nM [ 3 H]CFT was adjusted to 3.5, 5, 7, 17, 32, and 62 nM concentrations using unlabeled CFT. Parallel incubations with 30 mM unlabeled cocaine allowed estimation of nonspecific uptake and binding. Uptake assays were carried out for 5 min at 371C, followed by two washes each with 2 ml of Krebs-Ringer-Henseleit buffer. Binding assays were carried out for 2-3 h at 41C followed by three washes each with 1.5 ml of Krebs-RingerHenseleit buffer. Cells were solubilized in 0.5 ml of 1% SDS, and radioactivity was determined using a Beckman Instruments (Palo Alto, CA, USA) LS 6000 liquid scintillation counter at approximately 50% efficiency. Cells from parallel wells were solubilized in 0.5 ml of 1 N NaOH for protein amount measurements using a Bio-Rad Protein Assay solution (Bio-Rad). Studies of dopamine inhibition of 2-5 nM [
3 H]CFT binding used several concentrations of unlabeled dopamine in 50 mM ascorbic acid, 50 mM pargyline and 1 mM RO 41-0960.
All uptake competition experiments were carried out at 371C for 5 min. The tritium-labeled dopamine concentration used was 10 nM and the unlabeled competitors each had nine competition concentrations, ranging 0-1 mM. The corresponding inhibitors were included in the assay buffers as for uptake buffers, to prevent degradation of monoamines and cocaine. Each of the above experiments was carried out in duplicates. Unlabeled ligands were from RBI and all other chemicals were from Sigma.
Immunohistochemistry and Immunofluorescence Analyses
The protocol for immunohistochemical staining of COS cells expressing DATs using DAB has been described. 21 Briefly, COS cells transfected with DAT or DAT mutant plasmids were grown on coverslips in six-well plates for 2 days. Cells transfected with pcDEDAT provided a negative control. 21 Cells/DATs grown to approximately 80% confluence were quickly washed twice with 2 ml of PBS, fixed by 4% paraformaldehyde in PBS at 41C for 1 h. After four or five washes with PBS, endogenous peroxidase was inactivated by 10% methanol and 0.6% H 2 O 2 in PBS for 10 min at room temperature. After three washes with PBS, nonspecific protein binding was blocked by incubation in 1 ml of augmented TBS [TBS with 2% skim milk powder (Fluka Chemical Corp., Ronkonkoma, NY, USA), 0.2% Triton X-100, and 0.01% Na azide] for 1 h. A rabbit antibody raised against the C-terminus of rDAT was used as the primary antibody at a dilution of 1 : 1500; cells were incubated overnight at room temperature and then washed three times with 5 ml of augmented TBS. Cells were incubated for 1 h with biotinylated goat anti-rabbit IgG (Vector Laboratories, Burlingame, CA, USA), diluted 1 : 333 in TBS, washed three times with TBS, and incubated for 1 h with avidin-biotin complex solution prepared 30 min before use (Vectastain Elite Peroxidase ABC Kit; Vector Laboratories). After three washes with TBS, labeling was visualized by 1-min reaction with a freshly prepared solution containing 1.4 mM diaminobenzidine tetrahydrochloride, 1.6 mM NiCl 2 , and 2.2 mM H 2 O 2 in TBS. Stained cells on coverslips were washed three times with TBS, dehydrated, mounted on microscope slides, and examined for semiquantitative assessments of the patterns of DAT immunoreactivity. Wildtype expression patterns of DAT immunoreactivity were examined independently by an observer unaware of the genotypes.
Immunofluorescence assay of COS/DATs was carried out as follows. COS cells/FLAG-or c-myc-DATs were grown on coverslips, as described above. After being fixed with 4% paraformaldehyde, cells were rinsed twice with PBS containing 1 mM MgCl 2 /0.1 mM CaCl 2 and blocked with augmented TBS [TBS with 2% skim milk powder, 0.2% Triton X-100, 1 mM MgCl 2 /0.1 mM CaCl 2 , 0.01% Na azide] for 1 h at room temperature. The blocking solution then was aspirated and the cells were rinsed once with TBST (TBS containing 0.2% Triton X-100, 1 mM MgCl 2 /0.1 mM CaCl 2 ). The coverslips were incubated with the primary antibodies (anti-FLAG M-1 mAb and/or rabbit polyclonal anti-c-myc from Research Diagnostics, Inc., Flanders, NJ, USA) each at a concentration of 10 mg/ml in TBST for 1 h. The primary antibody was aspirated, and the cells were washed four times with TBST for 7 min per incubation. After washing, the cells were incubated with secondary antibodies [Alexa Fluor 594 goat anti-mouse IgG (H&L) and Alexa Fluor 488 goat anti-rabbit IgG (H&L), Molecular Probes, Eugene, OR] diluted 1 : 200 in TBST for 1 h. The secondary antibodies were removed and the cells were washed four times with TBST (7-min incubations each), and once with PBS. Coverslips were then mounted onto slides using the ProLong Antifade Kit (Molecular Probes) and allowed to air dry in darkness overnight. Coverslips were then sealed with Clarion nails. Fluorescence images were obtained via a ZEISS LSM 410 Invert Laser Scan Microscope System, at excitation/emission of 543/612 for Alexa Fluor 594 and 488/515 for Alexa Fluor 488. Z-sections were obtained at a half of the cell height. 
Analyses
